Renal AL amyloidosis
AL amyloid · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Deposition of monoclonal immunoglobulin light-chain-derived amyloid fibrils in the kidney causing nephrotic-range proteinuria and progressive renal failure, usually from an underlying plasma cell clone. Rapid diagnosis and clone-directed therapy improve organ and overall survival.
Red flags
- Cardiac involvement (raised troponin/NT-proBNP, heart failure, arrhythmia)
- Rapidly rising creatinine or heavy proteinuria
- Hypotension/autonomic failure
- Severe nephrotic syndrome with thrombosis
- Gastrointestinal bleeding or malabsorption (systemic amyloid)
Assessment
Differential diagnosis
- AL (light-chain) amyloidosis
- AA (serum amyloid A) amyloidosis
- Monoclonal immunoglobulin deposition disease
- Diabetic nephropathy (other nephrotic cause)
- Primary membranous nephropathy
- Hereditary amyloidosis
Investigations
- Serum/urine electrophoresis and serum free light chains with ratio
- Urine ACR/PCR (often nephrotic-range) and renal function
- Serum albumin, NT-proBNP/troponin (cardiac involvement)
- Renal (or other tissue) biopsy with Congo red staining and amyloid typing (mass spectrometry)
- Bone marrow biopsy for plasma cell clone
- Echocardiogram/cardiac MRI for cardiac amyloid
Management
- Suspect in unexplained nephrotic-range proteinuria, especially with cardiac or multisystem features
- Screen for a monoclonal protein with serum/urine electrophoresis and serum free light chains
- Confirm amyloid histologically (Congo red apple-green birefringence) and, critically, type it (mass spectrometry) to distinguish AL from AA/hereditary
- Assess organ involvement, especially cardiac (NT-proBNP, troponin, echo) which dominates prognosis
- Identify the underlying plasma cell/B-cell clone with bone marrow biopsy
- Refer urgently to haematology for clone-directed therapy (bortezomib-based regimens, often with daratumumab)
- Consider autologous stem cell transplantation in selected fit patients
- Provide supportive nephrology care: RAAS blockade, BP and oedema management, nephrotic complication prophylaxis
- Monitor haematological response (free light chains) and organ response
- Manage cardiac amyloid carefully (avoid hypotension, cautious diuretics, arrhythmia risk)
- Plan renal replacement therapy if end-stage disease develops
- Coordinate specialist amyloidosis centre follow-up
Drugs & doses
Bortezomib-based regimen (e.g. daratumumab-bortezomib-cyclophosphamide-dexamethasone) per haematology
Dexamethasone (component of clone-directed therapy, dosed per protocol)
Ramipril 2.5-10 mg PO daily (nephroprotection, as tolerated by BP)
Furosemide titrated for nephrotic oedema (cautious if cardiac amyloid)
Anticoagulation/thromboprophylaxis for nephrotic hypercoagulability per risk
Disposition
Joint nephrology-haematology (national amyloidosis centre) management. Urgent clone-directed therapy. Cardiology input for cardiac involvement; transplant only after clonal control.
Complications & pitfalls
- Progressive renal failure
- Cardiac amyloid with heart failure and sudden death
- Nephrotic complications (thrombosis, infection)
- Autonomic neuropathy and hypotension
- Treatment toxicity
- Recurrence in transplanted kidney if clone untreated
Exam pearls
- Typing amyloid (AL vs AA vs hereditary) changes treatment entirely — never assume AL
- Cardiac involvement dominates prognosis — always assess the heart
- Serum free light chains are both diagnostic and a treatment-response marker
- Clone-directed haematology therapy, not just supportive care, is essential
- Be cautious with diuretics and antihypertensives in cardiac amyloid (hypotension risk)
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.